Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.58 |
| ▸ | NAMPT | P43490 | 3/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 5/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30793545 | 0.92 | NR1H2 (0.56) | NR1H2NAMPTESR2MAPTMAPK1 | |
| SCHEMBL31535874 | 0.90 | NR1H2 (0.53) | NR1H2NAMPTESR2MAPTMAPK1 | |
| SCHEMBL8223979 | 0.89 | NR1H2 (0.55) | NR1H2NAMPTESR2MAPTMAPK1 | |
| SCHEMBL6890800 | 0.87 | NR1H2 (0.62) | NR1H2NAMPTESR2MAPTMAPK1 | |
| SCHEMBL30508929 | 0.86 | NAMPT (0.44) | NR1H2NAMPTESR2MAPTMAPK1 | |
| SCHEMBL6111584 | 0.85 | SPR (0.45) | NR1H2NAMPTMAPTMAPK1SPR | |
| SCHEMBL6110578 | 0.82 | LMNA (0.47) | NR1H2NAMPTMAPTSPRPSEN1 | |
| SCHEMBL13373596 | 0.82 | RIPK1 (0.48) | NR1H2NAMPTSPR | |
| SCHEMBL31549281 | 0.81 | NR1H2 (0.55) | NR1H2NAMPTESR2MAPTMAPK1 | |
| SCHEMBL26703719 | 0.81 | NR1H2 (0.52) | NR1H2NAMPTESR2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570634-B2 | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2026-03-10 | — | — | US | disclosed |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3883576-B1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4626888-A1 | COMPOUNDS | Redx Pharma Limited (GB) | 2025-10-08 | — | — | EP | disclosed |
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-12414952-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2025-09-16 | — | — | US | disclosed |
| CN-120129485-A | Methods, compositions, and systems for assessing visual function | 英属开曼群岛商倍亮生物有限公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2025099451-A1 | NEW COMPOUNDS AND METHODS | Transition Bio Limited (GB) | 2025-05-15 | — | — | WO | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| WO-2005065779-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1539766-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1057814-B1 | TETRAHYDROBENZINDOLE DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
| WO-2003104236-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
| US-6498251-B1 | Tetrahydrobenzindole derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| EP-1057814-A1 | TETRAHYDROBENZINDOLE DERIVATIVES | Meiji Seika Kaisha, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063735-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | NR1H2 393/4885NAMPT 1552/4885ESR2 290/4885 |
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | NR1H2 51/4885NAMPT 4072/4885ESR2 363/4885 |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | NR1H2 2734/4885NAMPT 2959/4885ESR2 704/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | NR1H2 1189/4885NAMPT 612/4885ESR2 2737/4885 |
| US-12414952-B2 | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2B, ADORA2A, ADORA3 | NR1H2 2257/4885NAMPT 1958/4885ESR2 640/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | NR1H2 4660/4885NAMPT 1143/4885ESR2 4439/4885 |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA1 | NR1H2 746/4885NAMPT 3159/4885ESR2 918/4885 |
| US-12570634-B2 | Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof | USP1, USP2, USP3 | NR1H2 4212/4885NAMPT 4622/4885ESR2 2572/4885 |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | NR1H2 393/4885NAMPT 1552/4885ESR2 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.